Deutsche Bank analyst Dan Leonard maintained a Hold rating on Hologic (NASDAQ: HOLX) today and set a price target of $42. The company’s shares closed yesterday at $39.64.
Leonard has an average return of 10.1% when recommending Hologic.
According to TipRanks.com, Leonard is ranked #1595 out of 4774 analysts.
Currently, the analyst consensus on Hologic is Moderate Buy and the average price target is $44.33, representing an 11.8% upside.
In a report released today, Canaccord Genuity also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
The company has a one-year high of $46.80 and a one-year low of $35.33. Currently, Hologic has an average volume of 2.47M.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HOLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health.
